UK panel rejects Kymriah for adults with lymphoma due to cost

September 19, 2018
An independent body that offers guidance to improve health and social care in England recommended against the use of tisagenlecleucel, a chimeric…
Feature

UCLA researchers receive grant to study combination therapy for lung cancer

September 18, 2018
Researchers at UCLA received $12 million to conduct a study of pembrolizumab in combination with patients’ genetically modified immune cells…
FDA News

FDA approves Lumoxiti for pretreated hairy cell leukemia

September 13, 2018
The FDA approved moxetumomab pasudotox-tdfk injection for the treatment of adults with relapsed/refractory hairy cell leukemia who have received at…
In the Journals Plus

Obinutuzumab-venetoclax shows activity for chronic lymphocytic leukemia

September 13, 2018
Bendamustine followed by obinutuzumab and venetoclax appeared safe and effective for treatment of patients with chronic lymphocytic leukemia…
In the Journals Plus

Fatal toxic events possible, but rare, with immune checkpoint inhibitors

September 13, 2018
Fatal toxic events occurred in about 0.3% to 1.3% of patients treated with immune checkpoint inhibitors, according to a meta-analysis of adverse…
FDA News

FDA grants priority review to Keytruda for PD-L1-positive NSCLC

September 12, 2018
The FDA granted priority review designation to a supplemental biologics license application for pembrolizumab for the treatment of non-small cell…

Avelumab plus axitinib improves PFS in advanced renal cell carcinoma

September 11, 2018
Treatment with avelumab and axitinib improved PFS among patients with advanced renal cell carcinoma compared with sunitinib monotherapy, according to…
In the Journals Plus

Immunotherapy shows promise for HIV-associated Kaposi’s sarcoma

September 7, 2018
Anti-PD-1 immune checkpoint inhibitors demonstrated high efficacy with low toxicity in a small cohort of patients with HIV-positive Kaposi’s…
In the Journals Plus

Anti-PD-1 drugs may cause hyperprogressive disease in lung cancer

September 6, 2018
Patients with advanced non-small cell lung cancer who underwent treatment with PD-1 and PD-L1 inhibitors had higher rates of hyperprogressive disease…

CAR T-cell therapy appears safe for multiple myeloma

September 6, 2018
The chimeric antigen receptor T-cell therapy P-BCMA-101 appeared safe among patients with relapsed/refractory multiple myeloma, according to the…